// App-Quantinova.ai

e20627 : Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis.

Researchers

Presenter

  • Martin Sebastian

Principal Investigators

  • Ute Klinkhardt

Medical Centers

  • Medizinische Klinik II Hamatologie/Onkologie, Rheumatologie, Infektiologie, HIV Klinikum der J.W. Goethe-Universitat Frankfurt, Frankfurt Am Main, Germany

  • Curevac GMBH, Tuebingen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • CVac

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01915524

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved